Analyst Reco. Spruce Biosciences, Inc.

Equities

SPRB

US85209E1091

Market Closed - Nasdaq Other stock markets 02:00:01 07/05/2024 am IST			5-day change	1st Jan Change
0.7542 ^USD	+1.32%		+6.23%	-74.26%

15/03	North American Morning Briefing : Inflation -2-	DJ
14/03	Top Midday Decliners	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Downgrades Spruce Biosciences to Neutral From Buy	14/03	MT
JMP Securities Adjusts Spruce Biosciences' Price Target to $3 From $8, Maintains Market Outperform Rating	14/03	MT
Leerink Partners Downgrades Spruce Biosciences to Market Perform From Outperform, Adjusts Price Target to $2 From $9	14/03	MT
Guggenheim Downgrades Spruce Biosciences to Neutral From Buy	14/03	MT
Ladenburg Thalmann Downgrades Spruce Biosciences to Neutral From Buy	14/03	MT
Spruce Biosciences Downgraded by RBC to Sector Perform From Outperform, Price Target Cut to $2 From $9, Shares Plunge Pre-Bell; Speculative Risk Kept	14/03	MT
RBC Lifts Price Target on Spruce Biosciences to $9 From $8, Cites Improved Chances of Congenital Adrenal Hyperplasia Program Success; Outperform, Speculative Risk Kept	26/02	MT
Guggenheim Initiates Spruce Biosciences at Buy Rating With $10 Price Target	21/02	MT
SVB Securities Upgrades Spruce Biosciences to Outperform From Market Perform, Adjusts Price Target to $9 From $3	08/23/08	MT
Oppenheimer Adjusts Spruce Biosciences Price Target to $7 From $8, Maintains Outperform Rating	18/23/18	MT
JMP Securities Adjusts Spruce Biosciences' Price Target to $8 From $7, Keeps Market Outperform Rating	16/23/16	MT
HC Wainwright Adjusts Spruce Biosciences' Price Target to $10 From $20	23/23/23	MT
RBC Trims Price Target on Spruce Biosciences to $8 From $9, Keeps Outperform, Speculative Risk	13/23/13	MT
Oppenheimer Adjusts Spruce Biosciences Price Target to $8 From $13, Maintains Outperform Rating	17/22/17	MT
JMP Securities Starts Spruce Biosciences at Market Outperform With $8 Price Target	16/22/16	MT
SVB Leerink Adjusts Spruce Biosciences' Price Target to $3 from $5, Keeps Market Perform Rating	16/22/16	MT
RBC Cuts Price Target on Spruce Biosciences to $9 From $13, Maintains Outperform Rating, Speculative Risk Qualifier	15/22/15	MT
Ladenburg Thalmann Starts Spruce Biosciences at Buy With $6 Price Target	08/22/08	MT
Credit Suisse Lowers Spruce Biosciences' Price Target to $4 from $6, Maintains Outperform Rating	14/22/14	MT
Oppenheimer Initiates Coverage on Spruce Biosciences With Outperform Rating, $15 Price Target	17/21/17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Spruce Biosciences, Inc.

Equities

SPRB

US85209E1091

Analyst Reco.

Filters